Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 3, 2001, Pages 222-228

  Yule, S M ^a   Price, L ^a   Cole, M ^a   Pearson, A D J ^a   Boddy, A V ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Autoinduction; Cyclophosphamide; Cytochrome P450; Drug metabolism

Indexed keywords

CYCLOPHOSPHAMIDE; ACICLOVIR; AMOXICILLIN; AMPHOTERICIN B; BECLOMETASONE; CARBAMAZEPINE; CARBOPLATIN; CEFALEXIN; CEFTAZIDIME; CHLORPHENIRAMINE; CISPLATIN; CYCLIZINE; DEXAMETHASONE; DIHYDROCODEINE; DOXORUBICIN; FLUCONAZOLE; FUROSEMIDE; HYDRALAZINE; IMIPENEM; MESNA; METHOTREXATE; METOCLOPRAMIDE; NYSTATIN; PARACETAMOL; PREDNISOLONE; PROPRANOLOL; RANITIDINE; SALBUTAMOL; TEICOPLANIN; UNINDEXED DRUG;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD; CHILD; COMPARATIVE STUDY; DENSITOMETRY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; NEOPLASM; NONPARAMETRIC TEST; PRESCHOOL CHILD; THIN LAYER CHROMATOGRAPHY; CANCER CHEMOTHERAPY; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG INFUSION; DRUG METABOLISM; PRIORITY JOURNAL;

ADOLESCENT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, THIN LAYER; CYCLOPHOSPHAMIDE; DENSITOMETRY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 0034743355     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000220     Document Type: Article

References (38)

1. Comparison of the sensitivity of normal haematopoetic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo
2. The comparative effects of selected cytotoxic agents on transplanted haematopoetic cells
3. Oxazaphosphorine cytostatics: Past-present-future. Seventh Cain Memorial Award Lecture
4. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide. Asta Z 7557)
5. Influence of schedule upon alkylating agent cytotoxicity in vitro and in vivo
6. Preclinical studies relating to the use of thiotepa in the high dose setting alone and in combination
7. Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies
8. Continuous-infusion cyclophosphamide plus vincristine cytosine-arabinoside and prednisolone for refractory acute lymphoblastic leukaemia in adults
9. Intermittent continuous IV infusion of high-dose cyclophosphamide for remission induction in acute lymphocytic leukaemia
10. Infusional cyclophosphamide, doxorubicin and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favouring infusional administration of chemotherapy
11. Comparison of continuous infusion and bolus administration of ifosfamide in children
12. Phase I and pharmacokinetic study of irinotecan administered as a low dose, continuous intravenous infusion over 14 days in patients with malignant solid tumours
13. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation
14. Metabolism of oxazaphosphorines
15. Identification of human liver aldehyde dehydrogenases that catalyse the oxidation of aldophosphamide and retinaldehyde
16. Cyclophosphamide metabolism in children
17. Adapt II users guide
18. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
19. A prospective randomised trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors
20. 24-Hour infusion of cis-platinum in head and neck cancers
21. Current dosage and schedule issues in the development of paclitaxel (TAXOL)
22. Response to ifosfamide and mesna: 124 Previously treated patients with metastatic or unresectable sarcoma
23. Ifosfamide by continuous infusion to prevent encephalopathy
24. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines
25. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients
26. Urinary excretion of the enantiomers of ifosfamide and its in-active metabolites in children
27. Differential activation of cyclophosphamide and ifosfamide by cytochromes P4502B and 3A in human liver microsomes
28. Fractionated administration of high-dose cyclophosphamide: Influence on dose-dependent changes in pharmacokinetics and metabolism
29. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,2-bis(2-chloroethyl)-1-nitrosourea
30. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients
31. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five day continuous infusion
32. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumour response
33. Dose-dependent enzyme induction
34. The 1986 Bernard B Brodie award lecture. The genetic regulation of drug-metabolising enzymes
35. The effect of fluconazole on cyclophosphamide metabolism in children
36. Plasma concentrations of 4-hydroperoxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation
37. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion
38. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism